Sectors
PHVS
Pharvaris N.V.
35.89
1 x 24.48
1 x 35.00
bid
ask
+
1.05
3.00%
09:36 AM
timesize
| Ytd | 29.32% | |
| 1y | 78.36% |
34.84
day range
35.22
20.36
52 week range
36.60
| Open | 34.84 | Prev Close | 34.84 | Low | 34.84 | High | 35.22 | Mkt Cap | 2.45B |
| Vol | 2.12K | Avg Vol | 425.73K | EPS | -3.19 | P/E | -11.02 | Forward P/E | -11.96 |
| Beta | -2.31 | Short Ratio | 2.09 | Inst. Own | 85.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 33.20 | 200-d Avg | 28.31 | 1yr Est | 48.39 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.75 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.82 | -0.7 | 0.12 | 14.83% |
| 2026-04-02 | 2025-12 | -0.71 | -0.85 | -0.13 | -18.34% |
| 2025-11-12 | 2025-09 | -0.78 | -0.7 | 0.08 | 10.26% |
| 2025-08-12 | 2025-06 | -0.87 | -0.94 | -0.07 | -8.05% |
| 2025-05-13 | 2025-03 | -0.8 | -0.89 | -0.09 | -11.25% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-15 | Wells Fargo | Upgrade | Overweight | |
| 2026-06-25 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform | |
| 2026-04-07 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-06 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-14 | ABELE STEFAN | Chief Operating Officer | 35.19K | Sale |
| 2026-05-19 | BJORK ELISABETH | Director | 15.17K | Sale |
| 2026-05-14 | GLASSMAN ROBERT R. | Director | 10.50K | Sale |
| 2026-06-29 | LESAGE ANNE SIMONNE J PH.D. | Officer | 0.00 | Sale |
| 2026-06-25 | LU PENG | Officer | 65.63K | Sale |
| 2026-07-12 | MODIG BERNDT B.A.E | Chief Executive Officer | 1.08M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | General Atlantic, L.P. | 8.03M | 280.37M | 12.28% |
| 2026-03-30 | FMR, LLC | 6.28M | 219.39M | 9.61% |
| 2026-03-30 | Foresite Capital Management IV, LLC | 4.78M | 166.82M | 7.31% |
| 2026-03-30 | venBio Partners LLC | 4.64M | 161.96M | 7.09% |
| 2026-03-30 | Viking Global Investors, L.P. | 3.65M | 127.54M | 5.59% |
| 2026-03-30 | Eqt Fund Management S.a R.l. | 3.42M | 119.55M | 5.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.37M | 47.94M | 2.10% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 800.00K | 27.93M | 1.22% |
| 2026-05-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 644.59K | 22.50M | 0.99% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 500.00K | 17.45M | 0.76% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 399.48K | 13.95M | 0.61% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 331.53K | 11.57M | 0.51% |